U.S.-Backed Researchers Use AI to Probe for Weaknesses in Drug Supply Chains

Any overreliance on foreign inputs in drug supply chains could leave the U.S. open to dire shortages in the event of conflict or natural catastrophe. The White House has flagged the potential disruption of the pharmaceutical supply chain as a national-security issue, saying these drugs are essential to the health and prosperity of the country. "The ever-changing threat environment, both natural and man-made, gives rise to numerous unforeseen challenges, such as to the pharmaceutical supply chain," said Jennifer Foley, a deputy director in DHS's science and technology directorate. Quantifind Inc., a company that normally does risk screening for financial institutions, will do the work, looking into supply chains for the Cross-Border Threat Screening and Supply Chain Defense Center of Excellence, a government-backed research center connected with Texas A&M University. Our Morning Risk Report features insights and news on governance, risk and compliance.